Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ucb S.A. (OP: UCBJF ) 194.85 -5.15 (-2.58%) Streaming Delayed Price Updated: 12:20 PM EST, Jan 7, 2025 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 200 Open 196.28 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 200.00 Today's Range 194.85 - 196.28 52wk Range 100.00 - 200.00 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside November 20, 2024 UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024. Via Benzinga FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease November 20, 2024 FDA approves UCB's Bimzelx for adults with moderate to severe hidradenitis suppurativa, supported by Phase 3 trials showing significant symptom improvement. Via Benzinga Exposures Product Safety Performance YTD -2.58% -2.58% 1 Month -0.52% -0.52% 3 Month +5.90% +5.90% 6 Month +30.03% +30.03% 1 Year +94.85% +94.85% More News Read More Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial September 24, 2024 Via Benzinga Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage September 10, 2024 Via Benzinga Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB August 29, 2024 Via Benzinga Exposures Product Safety UCB's Rare Childhood Epilepsy Drug Scores FDA Approval March 28, 2022 Via Benzinga Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies August 26, 2024 Via Benzinga There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target January 02, 2024 Via Benzinga Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst September 28, 2023 Via Benzinga Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts August 31, 2023 Via Benzinga FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults June 27, 2023 Via Benzinga Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path February 14, 2023 Via Benzinga Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane February 08, 2022 Via Benzinga UCB's Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study January 21, 2022 Via Benzinga UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights January 19, 2022 Via Benzinga UCB Gets EU Approval For Bimekizumab In Psoriasis August 25, 2021 Via Benzinga Stock Quote API & Stock News API supplied by www.cloudquote.io Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
